Good point.

If DCVax-L is approved, could a GBM patient decline chemo/radiation and only opt for the vaccine?

I think U.S. federal law dictates that FDA clinical review trials be designed with minimum statistical thresholds in order for a drug or device to be approved. But I agree with your post. You would think equaling standard of care with a product that has DCVax's safety record would be sufficient for approval.

Your comment is accurate and fair. Let's call it the whale omelette factor.

I suspect few people even know the half of it.

I see the same stuck volume for NWBO on my TD Ameritrade account, but my customized position page which includes volume accurately displays current daily volume for NWBO. Hope this helps.

I am willing to wait because I trust that NWBO, the DMC, and the FDA will come through on their parts. Waiting has a purpose, and it's to ensure that all the stakeholders, especially the patients, don't miss out on this imminent paradigm shift in the way cancers are treated.

This is your moment. I am happy for you.

Jeez, who peed on your cornflakes this morning?

Like

I would also like to pray for your wife. Are you comfortable giving us her first name? I understand if you are not due to privacy issues.

History tells us that hedge funds don't always win.

Biggest jump in awhile.

Cherrytree, here's one for you...a couple close friends are aware of the fact that I've spent a lot of time learning about and investing in biotech. Awhile back when they asked me what my picks were, I declined to answer for the reasons you and reg alluded to. I didn't want to chance them blaming me for losing their money and told them as much, but I still managed to alienate them in the process. Sometimes you just can't win. Now I keep my big mouth shut regarding all things financial with friends and family. Silent but generous is my motto. Thanks again to everyone who contributes to this board, past, present, and future. And to NWBO, those who support them, and all the cancer patients out there who stand to benefit from the DCVax platform, I wish you godspeed.

Look to August. Keep fighting the good fight.

I think you are on to something franky: with NWBO's connections, certainly they could have found at least one individual with the means and willingness to help get DCVax-L to the finish line.

Tell your son if he can wait 3-5 years, you may be able to buy him a Jeep dealership. ;)

Hope, jd, Cherry, et al., I admire your undeterred resolve and perseverance when so many others are warning us of impending doom.

No, dilution is just the fat lady choking on a chicken bone.

Exactly. Don't hold your breath.

Scammers Used SeekingAlpha for Bogus Stock Promotions, SEC Says
Where's the other half of the story, SEC?
https://www.bloomberg.com/news/articles/2017-04-10/scammers-used-seekingalpha-for-bogus-stock-promotions-sec-says

That's yet another red herring. The source is peer-reviewed and still completely valid.

Day trading woes.

IF you want to dig a little deeper, you will learn that he and NWBO share common interests. Credible news sources are telling a different story than yours.

Lucky dogs. I managed to get down to the low $2s. Godspeed.

You will find the answer to your question in the material above. GL

Hang on, NWBO may steady your ship.

This short volume chart for NWBO yesterday supports your comment:

...to the extent that all the patients in the trial have brain cancer.

It's lonely at the top.

Or maybe the sound of another soul on its way to the hereafter.

https://www.inspire.com/Cancer-Inspire/journal/first-cancer-moonshot-recommendation-is-more-patient-data/?ref=as&asat=478388416

SEPTEMBER 9, 2016 AT 11:03 AM 146 REPLIES SHARED WITH THE PUBLICFOLLOW POST PROBLEM?

By Radha_Inspire
Digital Editor, Inspire

The latest Cancer Moonshot report from a panel of top-tier cancer experts lays out 10 recomme. ations to speed progress in fighting cancer. 

The first recommendation is to ask patient to help create a large database of tumor profiles. This information will also pre-register these patients for relevant clinical trials down the line. 

“Many patients are eager to provide their data, and gathering this information in a linked network of databases would enable more precise knowledge about what works, in whom, and in which types of cancer,” the panel wrote in the report. “[Pre-registration will enable] them or their physicians to be contacted if their tumor’s molecular characteristi cs made them eligible for new clinical trials.” 

The full list of recommendations from the 28-member panel is: 

A. Establish a network for direct patient involvement 
B. Create a clinical trials network devoted exclusively to immunotherapy 
C. Develop ways to overcome cancer’s resistance to therapy 
D. Build a national cancer data ecosystem 
E. Intensify research on the major drivers of childhood cancers 
F. Minimize cancer treatment’s debilitating side effects 
G. Expand use of proven cancer prevention and early detection strategies 
H. Mine past patient data to predict future patient outcomes 
I. Develop a 3-D cancer atlas 
J. Develop new cancer technologies 

Although the Cancer Moonshot has a budget of nearly $1 billion, a recent article in the Washington Post noted that carrying out these recommendations would require millions more dollars, and it’s unclear if the US Congress could allocate further funds for them. 

But the report does reflect an approach that is data-driven and seeks involvement from patients, as when the Moonshot initiative and the NIHcalled for opinions about how to improve access to clinical trials. 

How would you feel about banking a tumor profile and possibly getting an early heads-up for future clinical trials? Please share your thoughts in the comments below. 

The content provided by this Inspire account is for general informational purposes only and does not necessarily reflect the views and opinions of any organization. The content should not be used as a substitute for professional medical advice, diagnoses, or treatment. Please consult your healthcare provider about any questions you may have regarding a medical condition.

That's the way I look at it, too.

Your conditional negative has some merit, but it's also like saying if DCVax-L PhIII is approved, I'm gonna buy a boat.

TC, I think I understand what you are getting at. Below is an excerpt about a company uplisting to OTC-QB where it states the benefit of attracting institutional investors. So, I think you are saying that it's not impossible but highly unlikely NWBO will receive institution investors after delisting from NASDAQ and that technically, an agreeement wouldn't have to be in hand, but it would from a practical standpoint. Maybe many institutional investors are prohibited from investing in the OTCQB. But I can't help but think if there ever were a scenario whereby an institutional investor was going to make an exception, NWBO would be the one if DCVax- Phase III results are positive.

Evans Brewing Company Begins Trading on the OTCQB

IRVINE, CA--(Marketwired - Aug 22, 2016) - Evans Brewing Company (OTCQB: ALES), a producer of award-winning premium craft beers, today announced that its common stock has been approved for, and has begun trading on, the OTCQB® Venture Marketplace (OTCQB). The uplisting to the OTCQB is part of the company's strategy to provide a high level of transparency for its shareholders and is expected to provide opportunities to attract broker dealers and retail and institutional investors that require the reporting and disclosure of the OTCQB tier. 

The OTCQB is considered by the Securities and Exchange Commission (SEC) as an "established public market" for the purpose of determining the public market price when registering securities for resale with the SEC. The OTC Pink is not considered as such and most broker dealers will not trade or recommend OTC Pink stocks. Because the OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements, the majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

About what?

Nevertheless, Nissan's decided strategy is for its common shares to be made available for purchase OTC via ADRs.

TOKYO (July 24, 2009) - The American Depositary Receipts ("ADR") of Nissan Motor Co. Ltd. (TSE: 7201; NASDAQ: NSANY), each of which represents the right to receive two common shares of Nissan, will transition from the NASDAQ Stock Market ("NASDAQ'') and commence trading on the over-the-counter ("OTC") market at the close of business on Friday, July 31, 2009.

On August 1, 2006, NASDAQ began operating as a national securities exchange and all listed issues were required to be registered under Section 12(b) of the U.S. Securities Exchange Act of 1934. However, at NASDAQ's request, the U.S. Securities and Exchange Commission granted a temporary three-year extension to allow companies that were traded on NASDAQ and exempt from registration pursuant to Rule 12g3-2(b) of the Act, such as Nissan, to continue trading on an unregistered basis. This extension will expire on Saturday, August 1, 2009.

As Nissan has determined not to register its common shares under Section 12(b), Nissan's ADRs will transition from NASDAQ to the OTC market after July 31, 2009. Nissan has also determined not to arrange for the listing of its ADRs or common shares on another national securities exchange. Its common shares will remain listed on the Tokyo Stock Exchange, which is Nissan's primary trading market.

Nissan will maintain its current ADR program with JPMorgan Chase Bank, N.A., and will continue to provide its annual and interim reports and other financial information on its Investor Relations website at http://www.nissan-global.com/EN/IR/.

If ADR holders have any inquiries, please contact the following:

Some large legitimate companies like Roche and Nissan prefer to be traded OTC. I agree that delisting was better than a R/S in the long run for shareholders. I also think LP will be able to raise needed funds after leaving NASDAQ. Looking forward to that press release that will turn things around once and for all.

Scripture aside, there's a lot of scientific data out there to the contrary. For example, http://www.newsmax.com/t/newsmax/article/635623

I know where you're coming from. Share price fluctuations in the biotech sector aren't for the faint of heart, so I don't blame you one bit for living vicarioulsly through the temporary misfortune of others. Moreover, I have never been in denial about the associated risk, but this game is not over yet. I still like where the company is sitting, and I am hoping and waiting patiently for positive Phase III results. That's why I didn't sell several months ago when pps was up 98%. So you see, today's pps means nothing to me.